Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Lipson

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|March 10, 2021
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPDJean Bourbeau, Mona Bafadhel, Neil C Barnes, et al.
Chronic Respiratory Disease|October 6, 2023
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?Edward M Kerwin, Paul W Jones, Leif H Bjermer, et al.
Respiratory Medicine|July 8, 2022
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPDFrançois Maltais, Claus F Vogelmeier, Edward M Kerwin, et al.
American Journal of Respiratory and Critical Care Medicine|April 1, 2022
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical TrialsPeter M A Calverley, Fernando J Martinez, Jørgen Vestbo, et al.
Therapeutic Advances in Respiratory Disease|October 30, 2020
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACTJosé M Marín, Luis Mateos, Juan Roldán, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2017
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Helen Barnacle, Ruby Birk, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 29, 2005
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipientVivek N Ahya, Alden M Doyle, James D Mendez, et al.
COPD|September 29, 2018
The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)Jinping Zheng, Nanshan Zhong, Changzheng Wang, et al.
Current Medical Research and Opinion|October 30, 2020
Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trialJinping Zheng, Nanshan Zhong, Changzheng Wang, et al.
American Journal of Respiratory and Critical Care Medicine|January 3, 2006
Risk factors for death of patients with cystic fibrosis awaiting lung transplantationRichard A Belkin, Noreen R Henig, Lianne G Singer, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
International Journal of Chronic Obstructive Pulmonary Disease|March 10, 2021
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPDJean Bourbeau, Mona Bafadhel, Neil C Barnes, et al.
Chronic Respiratory Disease|October 6, 2023
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?Edward M Kerwin, Paul W Jones, Leif H Bjermer, et al.
Respiratory Medicine|July 8, 2022
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPDFrançois Maltais, Claus F Vogelmeier, Edward M Kerwin, et al.
American Journal of Respiratory and Critical Care Medicine|April 1, 2022
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical TrialsPeter M A Calverley, Fernando J Martinez, Jørgen Vestbo, et al.
Therapeutic Advances in Respiratory Disease|October 30, 2020
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACTJosé M Marín, Luis Mateos, Juan Roldán, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2017
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Helen Barnacle, Ruby Birk, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 29, 2005
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipientVivek N Ahya, Alden M Doyle, James D Mendez, et al.
COPD|September 29, 2018
The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)Jinping Zheng, Nanshan Zhong, Changzheng Wang, et al.
Current Medical Research and Opinion|October 30, 2020
Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trialJinping Zheng, Nanshan Zhong, Changzheng Wang, et al.
American Journal of Respiratory and Critical Care Medicine|January 3, 2006
Risk factors for death of patients with cystic fibrosis awaiting lung transplantationRichard A Belkin, Noreen R Henig, Lianne G Singer, et al.
Pageof 12